NCT05041387 Data Collection of Standard Care of Patients in the EMG Section
| NCT ID | NCT05041387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
| Condition | Neuropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2031-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-06-24 with a primary completion date of 2031-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Most people who are referred to the EMG (Electromyography) Section of the NIH are enrolled into specific active studies. This allows researchers to learn about a range of rare neuromuscular disorders. But study criteria may not give researchers the chance to evaluate a single person or study a common symptom. Therefore, researchers want to assess people with neuromuscular disorders who are not currently enrolled in any NIH studies. They will perform tests on these individuals in the EMG Lab. Then they will create a repository of data that may be used for future research. This will help them learn more about these disorders. Objective: To retain data that is collected as part of participant visits to the NIH. Eligibility: People aged 18 and older who will be visiting the NIH for evaluation of their neuromuscular disorder. Design: Participants will be screened with a medical record review. Participants will have a physical exam. They will be evaluated for their neuromuscular disorder. They may have tests to learn more about how their nerves and muscles work that are called nerve conduction and EMG studies. Their muscles and nerves may be assessed with an ultrasound. Their ability to sweat may be measured. Their heart rate and blood pressure may be taken. Changes to their breathing or changes in their body position may be measured. Participant data will be given a unique numerical identifier that can be used if the data is shared. Data will be stored on a server and in a database. Participants will have 1-2 visits. Each visit will last less than 4 hours. They may be contacted for a follow-up visit.
Eligibility Criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * The patient or the patient's Legally Authorized Representative is capable of informed consent and signs the consent form. * Male or female, age 18 and over, no age limit * Possible neuromuscular disorder or neurodegenerative disorder. EXCLUSION CRITERIA: No other exclusion criteria for patients
Contact & Investigator
Tanya J Lehky, M.D.
PRINCIPAL INVESTIGATOR
National Institute of Neurological Disorders and Stroke (NINDS)
Frequently Asked Questions
Who can join the NCT05041387 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05041387 currently recruiting?
Yes, NCT05041387 is actively recruiting participants. Contact the research team at candida.silva@nih.gov for enrollment information.
Where is the NCT05041387 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT05041387 clinical trial?
NCT05041387 is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). The principal investigator is Tanya J Lehky, M.D. at National Institute of Neurological Disorders and Stroke (NINDS). The trial plans to enroll 200 participants.